Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T George

Showing results (631-640 of 771) with videos related to

Pageof 78
Sort By:
Journal of Community Health|June 1, 2025
Community-level Social Vulnerability and Cervical Cancer Mortality Among Young and Old Adults in the State of AlabamaPranali G Patel, Sabrina Chowdhury, Howard W Wiener, et al.
The Journal of Clinical Endocrinology and Metabolism|July 27, 2016
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled TrialJyothis T George, Rahul Kakkar, Jayne Marshall, et al.
Advanced Healthcare Materials|April 14, 2015
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killingPei Yun Teo, Chuan Yang, Lynsey M Whilding, et al.
Molecular Cell|December 5, 2023
ER chaperones use a protein folding and quality control glyco-codeKevin P Guay, Haiping Ke, Nathan P Canniff, et al.
Archives of Physical Medicine and Rehabilitation|October 6, 2009
Observation of amounts of movement practice provided during stroke rehabilitationCatherine E Lang, Jillian R Macdonald, Darcy S Reisman, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
Psychiatric Research and Clinical Practice|November 8, 2021
Common Factors Underlying Diverse Responses in Alcohol Use DisorderEsha Chebolu, Melanie L Schwandt, Vijay A Ramchandani, et al.
Journal of the American Heart Association|March 23, 2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialJoão Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trialMuthiah Vaduganathan, Silvio E Inzucchi, Naveed Sattar, et al.
Pageof 78

Showing results (631-640 of 771) with videos related to

Sort By:
Pageof 78
Journal of Community Health|June 1, 2025
Community-level Social Vulnerability and Cervical Cancer Mortality Among Young and Old Adults in the State of AlabamaPranali G Patel, Sabrina Chowdhury, Howard W Wiener, et al.
The Journal of Clinical Endocrinology and Metabolism|July 27, 2016
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled TrialJyothis T George, Rahul Kakkar, Jayne Marshall, et al.
Advanced Healthcare Materials|April 14, 2015
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killingPei Yun Teo, Chuan Yang, Lynsey M Whilding, et al.
Molecular Cell|December 5, 2023
ER chaperones use a protein folding and quality control glyco-codeKevin P Guay, Haiping Ke, Nathan P Canniff, et al.
Archives of Physical Medicine and Rehabilitation|October 6, 2009
Observation of amounts of movement practice provided during stroke rehabilitationCatherine E Lang, Jillian R Macdonald, Darcy S Reisman, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
Psychiatric Research and Clinical Practice|November 8, 2021
Common Factors Underlying Diverse Responses in Alcohol Use DisorderEsha Chebolu, Melanie L Schwandt, Vijay A Ramchandani, et al.
Journal of the American Heart Association|March 23, 2021
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialJoão Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trialMuthiah Vaduganathan, Silvio E Inzucchi, Naveed Sattar, et al.
Pageof 78